DK0934069T3 - Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser - Google Patents
Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelserInfo
- Publication number
- DK0934069T3 DK0934069T3 DK97923573T DK97923573T DK0934069T3 DK 0934069 T3 DK0934069 T3 DK 0934069T3 DK 97923573 T DK97923573 T DK 97923573T DK 97923573 T DK97923573 T DK 97923573T DK 0934069 T3 DK0934069 T3 DK 0934069T3
- Authority
- DK
- Denmark
- Prior art keywords
- agonist
- glucose metabolism
- adrenergic
- dopamine
- metabolism disorders
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 208000017170 Lipid metabolism disease Diseases 0.000 title 1
- 208000018914 glucose metabolism disease Diseases 0.000 title 1
- 239000000951 adrenergic alpha-1 receptor antagonist Substances 0.000 abstract 2
- 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 239000002288 dopamine 2 receptor stimulating agent Substances 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000000862 serotonergic effect Effects 0.000 abstract 2
- 239000000510 dopamine 1 receptor stimulating agent Substances 0.000 abstract 1
- 230000004153 glucose metabolism Effects 0.000 abstract 1
- 230000037356 lipid metabolism Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1737796P | 1996-05-07 | 1996-05-07 | |
| US1933696P | 1996-06-06 | 1996-06-06 | |
| PCT/US1997/007701 WO1997041873A1 (en) | 1996-05-07 | 1997-05-06 | Method and composition for the treatment of lipid and glucose metabolism disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0934069T3 true DK0934069T3 (da) | 2007-03-19 |
Family
ID=26689794
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97923573T DK0934069T3 (da) | 1996-05-07 | 1997-05-06 | Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP0934069B1 (da) |
| AT (1) | ATE344668T1 (da) |
| CA (1) | CA2254116C (da) |
| DE (1) | DE69736928T2 (da) |
| DK (1) | DK0934069T3 (da) |
| ES (2) | ES2393303T3 (da) |
| HK (1) | HK1108312A1 (da) |
| PT (1) | PT934069E (da) |
| WO (1) | WO1997041873A1 (da) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6366298B1 (en) | 1999-06-03 | 2002-04-02 | Netzero, Inc. | Monitoring of individual internet usage |
| US20040077679A1 (en) * | 2002-07-29 | 2004-04-22 | Cincotta Anthony H. | Therapeutic treatment for the metabolic syndrome and type 2 diabetes |
| US9655865B2 (en) | 2002-07-29 | 2017-05-23 | Veroscience, Llc | Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes |
| US8821915B2 (en) | 2002-08-09 | 2014-09-02 | Veroscience, Llc | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders |
| EP1870096A3 (en) * | 2003-04-29 | 2011-04-20 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss |
| HUE034290T2 (en) | 2003-04-29 | 2018-02-28 | Orexigen Therapeutics Inc | Preparations containing opioid antagonist and bupropion to affect weight loss |
| CA2630624C (en) | 2005-11-22 | 2013-08-06 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
| US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
| CN101573103A (zh) | 2006-11-09 | 2009-11-04 | 奥雷西根治疗公司 | 用于施用重量减轻药物的单位剂量包装和方法 |
| AU2013263800B2 (en) * | 2007-03-30 | 2016-05-05 | Veroscience Llc | Methods of treating metabolic syndrome using dopamine receptor agonists |
| US8741918B2 (en) | 2007-06-21 | 2014-06-03 | Veroscience Llc | Parenteral formulations of dopamine agonists |
| US20100035886A1 (en) | 2007-06-21 | 2010-02-11 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| WO2009062113A1 (en) * | 2007-11-07 | 2009-05-14 | Burnham Institute For Medical Research | Method and compounds for modulating insulin production |
| AU2015201255B2 (en) * | 2008-01-14 | 2016-05-19 | Veroscience, Llc | Parenteral formulations of dopamine agonists |
| CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
| US9352025B2 (en) | 2009-06-05 | 2016-05-31 | Veroscience Llc | Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders |
| JP6196041B2 (ja) | 2010-01-11 | 2017-09-13 | オレキシジェン・セラピューティクス・インコーポレーテッド | 大うつ病を有する患者において減量療法を提供する方法 |
| KR20230010811A (ko) | 2012-06-06 | 2023-01-19 | 오렉시젠 세러퓨틱스 인크. | 과체중 및 비만의 치료 방법 |
| US8969371B1 (en) | 2013-12-06 | 2015-03-03 | Orexigen Therapeutics, Inc. | Compositions and methods for weight loss in at risk patient populations |
| JP6978126B2 (ja) * | 2018-09-03 | 2021-12-08 | 代謝肥満サイエンス株式会社 | 肥満関連代謝疾患の改善剤 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3419293A (en) * | 1991-12-23 | 1993-07-28 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The | A therapeutic process for the treatment of the pathologies of type II diabetes |
-
1997
- 1997-05-06 ES ES06015512T patent/ES2393303T3/es not_active Expired - Lifetime
- 1997-05-06 CA CA002254116A patent/CA2254116C/en not_active Expired - Fee Related
- 1997-05-06 DE DE69736928T patent/DE69736928T2/de not_active Expired - Lifetime
- 1997-05-06 PT PT97923573T patent/PT934069E/pt unknown
- 1997-05-06 EP EP97923573A patent/EP0934069B1/en not_active Expired - Lifetime
- 1997-05-06 DK DK97923573T patent/DK0934069T3/da active
- 1997-05-06 WO PCT/US1997/007701 patent/WO1997041873A1/en active IP Right Grant
- 1997-05-06 ES ES97923573T patent/ES2277357T3/es not_active Expired - Lifetime
- 1997-05-06 AT AT97923573T patent/ATE344668T1/de not_active IP Right Cessation
- 1997-05-06 EP EP06015512A patent/EP1776955B1/en not_active Expired - Lifetime
-
2007
- 2007-10-09 HK HK07110914.5A patent/HK1108312A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69736928T2 (de) | 2007-06-28 |
| ATE344668T1 (de) | 2006-11-15 |
| DE69736928D1 (de) | 2006-12-21 |
| CA2254116A1 (en) | 1997-11-13 |
| EP1776955A1 (en) | 2007-04-25 |
| HK1108312A1 (en) | 2008-05-02 |
| EP1776955B1 (en) | 2012-08-15 |
| ES2277357T3 (es) | 2007-07-01 |
| WO1997041873A1 (en) | 1997-11-13 |
| EP0934069A4 (en) | 2002-12-04 |
| PT934069E (pt) | 2007-02-28 |
| ES2393303T3 (es) | 2012-12-20 |
| EP0934069A1 (en) | 1999-08-11 |
| EP0934069B1 (en) | 2006-11-08 |
| CA2254116C (en) | 2009-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0934069T3 (da) | Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser | |
| DK0867178T3 (da) | Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser | |
| DK0772451T3 (da) | Behandling af type II-diabetes mellitus med amylin-agonister | |
| LV11830A (lv) | Metode un ierice notekudens attirisanai | |
| DE69516866D1 (de) | Stereochemische wortmanninderivate | |
| DK0726765T3 (da) | Apparat og fremgangsmåde til fremstilling af faste former med styret frigivelse af den aktive bestanddel | |
| DK0789567T3 (da) | En fremgangsmåde til behandling af vaskulære hovedpiner | |
| DK0942751T3 (da) | Præparater til behandling af perifere nuropatier indeholdende antidepressiver og/eller monoaminoxidase-inhibitorer og/eller vitamin B12 og/eller prekursere til eller inducere af en neurotransmitter | |
| DE60025368D1 (de) | Verfahren zum identifizieren von prostaglandin d2 rezeptor modulatoren | |
| DE69815090D1 (de) | Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen | |
| TR200102515T2 (tr) | Egzersiz kaynaklı astma tedavisi için metod. | |
| ATE206915T1 (de) | Behandlung von angstzuständen | |
| KR890701099A (ko) | 기침 및 기관지 협착을 치료하기 위한 5-ht3 수용기 길항물질 | |
| EA199800864A1 (ru) | Способ лечения при боли, вызванной мигренью | |
| DK0674521T3 (da) | Fremgangsmåde til behandling af kronisk prostatitis med 17beta-N-tertbutylcarbamoyl-4-aza-5a-andost-1-en-3-on | |
| DK1385993T3 (da) | Fremgangsmåde til detektering og behandling af tuberøs sclerose kompleksrelaterede lidelser | |
| EA200100182A1 (ru) | Лечение состояний тревожности | |
| TR199701613T1 (xx) | Selim prostatik hiperplasyan�n tedavisi i�in melatonin agonistleri. | |
| EA199800858A1 (ru) | Способ лечения насморка или аллергического ринита | |
| Jordan | Behavioural and neurochemical correlates of drugs acting at imidazoline and α2-adrenoceptor binding sites | |
| EA200100248A1 (ru) | Новое применение таксоидных производных | |
| MX9710075A (es) | Antagonistas melatonina para el tratamiento en la hiperplasia prostatica benigna. |